Ono Enters into Research Collaboration with UK Dementia Research Institute

As for such molecules identified through the collaboration, Ono will generate drug candidates against those target molecules and work towards the development and commercialization of new drugs for the treatment of dementia. As for such molecules identified through the collaboration, Ono will generate drug candidates against those target molecules and work towards the development and commercialization of new drugs for the treatment of dementia. Ono dedicates our drug discovery efforts...

As for such molecules identified through the collaboration, Ono will generate drug candidates against those target molecules and work towards the development and commercialization of new drugs for the treatment of dementia.

Ono dedicates our drug discovery efforts focusing on oncology, immunology and neuroscience areas with the aim to create innovative drugs that can fulfill unmet medical needs. Through our active promotion of "open innovation," we have generated a number of innovative medicines. We will keep on being committed to creating innovative medicines, aiming to become a global specialty pharma based on our unique drug discovery approach through the open innovation.

UK DRI is a national research institution that brings together leading dementia researchers in the world from six prominent universities in the UK. Its aim is to provide therapeutic solutions for various types of dementia, including Alzheimer's disease. With over 750 researchers, the institute utilizes cutting-edge technologies such as multiomics (integrative analysis of genes, proteins, metabolites, etc.), induced pluripotent stem (iPS) cells, and data science, to unravel the pathogenetic mechanisms of dementia and develop effective treatments.

"We are pleased to collaborate with UK DRI who has world-leading research capabilities and research collaborative framework," said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono. "We expect that this partnership will lead to the discovery of innovative new therapeutic targets for dementia."

"We are delighted to partner with Ono Pharma, a company that shares our commitment to developing life-changing new drugs for dementia," said Dr Kay Penicud, Director of Innovation & Business at UK DRI. "This strategic collaboration leverages our complementary capabilities in discovery research and drug development. By working together, we aim to accelerate the translation of new research into clinical applications that will bring us closer to desperately needed treatments for those affected by dementia."

About UK DRI
UK DRI is a national research institute operated by world-leading experts in dementia research area, with funding from the Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK. University College London (UCL) is home to the operational headquarters of the UK DRI and forms the hub for research activities across the six national research centres, which are at UCL, the University of Cambridge, Cardiff University, the University of Edinburgh, Imperial College London and King's College London. The institute aims to provide better treatment options for dementia patients by enabling access to world-class research resources and fostering close collaboration among these universities, thus bringing together leading dementia researchers from around the world.

Logo - https://mma.prnewswire.com/media/1636289/4468691/ONO_PHARMA_USA_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ono-enters-into-research-collaboration-with-uk-dementia-research-institute-302021415.html